Catalyst Pharmaceuticals, Inc. announced the online publication in SAGE Open Medicine of the results of an investigator-sponsored Phase IIb clinical trial (MSK-001) evaluating Firdapse® (amifampridine phosphate) for the treatment of MuSK antibody positive Myasthenia Gravis (MuSK-MG). The positive topline results from this trial were previously announced, but the full results of safety, efficacy and other clinical data are now available online. The MSK-001 trial was a randomized, double-blind, placebo-controlled, double crossover design. The co-primary endpoints were statistically met (QMG score: p=0.0003 and MG-Activities of Daily Living Profile Score: p=0.0006) as well as the secondary endpoints. The study provided evidence that amifampridine phosphate was safe and effective in treating MuSK-MG patients. The study was conducted under the supervision of Silvia Bonanno, M.D. and her team at the Istituto Neurologico Carlo Besta in Milan, Italy.